Navigation Links
Cambrex Reports Second Quarter 2009 Results
Date:8/4/2009

s. The Company currently employs approximately 850 people worldwide. For more information, please visit www.cambrex.com.

                              CAMBREX CORPORATION
                          Statement of Profit and Loss
                 For the Quarters Ended June 30, 2009 and 2008
                                 (in thousands)

                                                  2009            2008
                                                       % of            % of
                                              Amount  Sales    Amount  Sales
                                              ------  -----    ------  -----

    Gross Sales                              $59,766  100.0%  $66,226  100.0%
         Allowances and Rebates                    5    0.0%      553    0.8%
                                              ------           ------
    Net Sales                                 59,761  100.0%   65,673   99.2%

         Other Revenues                         (480)  -0.8%      140    0.2%
                                              ------           ------

    Net Revenues                              59,281   99.2%   65,813   99.4%

         Cost of Goods Sold                   39,598   66.3%   46,002   69.5%
                                              ------           ------

    Gross Profit                              19,683   32.9%   19,811   29.9%

    Operating Expenses
         Selling, General and Administrative
          Expenses                             8,546   14.3%   11,410   17.2%
         Research and Development Expenses     2,161    3.6%    1,917    2.9%
         Restructuring Expenses                    -    0.0%      514    0.8%
         Strategic Alternative Costs               -    0.0%      398    0.6%
                                              ------           ------
    Total Operating Expenses      
'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
2. Cambrex Signs Agreement To Acquire ProSyntest AS
3. Cambrex Reports Fourth Quarter and Full-Year 2007 Results
4. Cambrex Customer Announced Recall
5. Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
6. Cambrex Presentation at The JPMorgan Healthcare Conference to be Webcast
7. Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products
8. Cambrex to Announce Fourth Quarter 2008 Financial Results on February 11, 2009
9. Cambrex Reports Fourth Quarter and Full Year 2008 Results
10. Cambrex Regains Compliance With Revised NYSE Listing Standards
11. Cambrex To Announce Second Quarter 2009 Financial Results on August 4, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... HealthDay Reporter SATURDAY, ... comparison, an experimental drug was more effective than standard ... patients. According to the study authors, the trial ... the new drug, dubbed LCZ696. In the ... enalapril (Vasotec), either died or were hospitalized due to ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 Liver ... the one vital organ that helps the body in barring ... as a store of energy. Liver also plays many important ... cholesterol, iron and glucose. , Many illnesses can affect ... just under the rib cage on the right side of ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... Dennis Thompson HealthDay ... An experimental Ebola drug previously given to two American aid ... deadly virus in laboratory tests, researchers report. The drug, ... even if they didn,t get the medication until five days ... of Ebola who were days or even hours away from ...
(Date:9/1/2014)... As well as having completed the Non ... counselor certification in Louisiana. , "I have ... program as well as the Counselor training program ... and professionally. I am not only dedicated to ... do so. As a Non Violent Crisis Intervention ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2
... ... offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital voice recorder ... consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in the United States, ...
... 9 June 2009 - Researchers have been seeking ... impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) ... may contribute to the underlying neurobiology of this ... stimulate NMDA receptors administered large amounts of substances, ...
... DNA binding compound has proved surprisingly effective at binding to ... touched within two minutes. The DNA binding properties of the ... the University of Warwick by Professor Mike Hannon and Professor ... of Birmingham). However the strength of its antibiotic powers have ...
... June 9 BioMarin Pharmaceutical Inc. (Nasdaq: ... clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) ... expects to initiate the Phase 2 clinical study in ... (IRB) approval from the clinical trial sites. The ...
... Protein Widely Expressed on Tumors and Tumor Blood Vessel ... Morphotek(R), Inc., a subsidiary of Eisai Corporation of North ... (FDA) cleared its investigational new drug (IND) application to ... tumors. MORAb-004 targets endosialin, a protein expressed on cells ...
... Bruce Matter has joined healthcare IT software provider, ... growth and client satisfaction. Peminic, with offices in Princeton, ... solutions to over 400 acute care and other healthcare ... legal matters. , , Teaming with hospitals, health ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:Animal model for schizophrenia identifies a novel approach for treating cognitive impairments 2Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 3Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 4Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates 2
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Global Generic Pharmaceuticals ... The Global Generic Pharmaceuticals Industry Report ... evaluation of the Global Generic Pharmaceuticals Industry Report. ...
... Ill., Dec. 8, 2010 Life Spine announced today ... the OCTAVE Posterior Fusion System, which is intended for ... achieving fusion in conjunction with bone graft. The U.S. ... to the OCTAVE System last month. ...
Cached Medicine Technology:Reportlinker Adds Global Generic Pharmaceuticals Industry Report 2Reportlinker Adds Global Generic Pharmaceuticals Industry Report 3Reportlinker Adds Global Generic Pharmaceuticals Industry Report 4Reportlinker Adds Global Generic Pharmaceuticals Industry Report 5Reportlinker Adds Global Generic Pharmaceuticals Industry Report 6Reportlinker Adds Global Generic Pharmaceuticals Industry Report 7
... Autoref / Ker Accuref K ... inch LCD color monitor. 3 ... range. 2.3 mm Minimum pupil ... light adjuster. Auto start function. ...
... is the child-friendly, portable autorefractor that ... adults. It can perform objective refraction ... cm) away even through glasses and ... and sounds engage the patient throughout ...
Neomycin and Polymyxin B sulfates and Dexamethasone ophthalmic ointment is a multiple dose anti-infective steroid combination in sterile ointment form for topical applications....
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
Medicine Products: